Oyster Point Pharma, Inc.

And welcome to Oyster Point Pharma's third quarter 2021 earnings conference call. My name is Jeff, and I'll be the operator today. After the company's formal remarks, there will be a question and answer session. At this time, I would like to turn the call over to Mr. Daniel Lochner, Oyster Point Pharma's chief financial officer. Please go ahead.

Good evening, everyone, and welcome to the Oyster Point Pharma Third Quarter Earnings Conference Call for the three-month ending September 30, 2021. This evening, we issued a press release containing our third quarter financial results and recent business highlights. In addition, our press release and our Form 10-Q that was filed with the SEC after the close of market today are available on our website under the Investor News section, at www.oysterpointrx.com. Joining us on our call today are Dr. Jeffrey Now, President and Chief Executive Officer of Oyster Point Pharma, and John Snizerenko, Chief Commercial Officer. Following Dr. Now, Mr. Snizerenko, and my prepared remarks, we will open the line for questions. During the call today, we will be making forward-looking statements regarding potential future events, including statements regarding Oyster Point Farms' potential future financial status and results of operations, and our plans and potential for success relating to commercializing deer bias. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from our future results, performance, and achievements expressed or implied by such statements. For description of these factors, please see our quarterly report on Form 10-Q for the quarters into September 30th, June 30th, and March 31st, 2021, and our annual report on Form 10-K for the year into December 31st, 2020, as filed with the SEC. I will now turn the call over to Dr. Jeffrey Naum, President and Chief Executive Officer of Wichita Point Pharma.

Thank you, Dan. Good evening, everyone, and thank you for joining us on our call today. to discuss our third quarter 2021 financial results and recent business highlights. As you may have seen in our Q3 earnings press release, we have achieved several important milestones during this quarter, the most important of which is the October 15th FDA approval of tear via nasal spray for the treatment of the signs and symptoms of dry eye disease. Tear via nasal spray is the first and only nasal spray and the first and only cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. The onboarding of our field force was completed during Q3 and we are proud to have one of the leading US eye care focused field forces in the industry. Last week we hosted our national sales meeting and had the opportunity to gather our talented group of territory representatives to prepare for our launch. I couldn't be more excited and impressed by the caliber of the field force that we have assembled here at Oyster Point Pharma This is a team that is motivated to make this launch a success. Following our national sales meeting, we are now pleased to announce that as of this past Monday, we have initiated the US launch of TearBio Nasal Spray for the treatment of the signs and symptoms of dry eye disease. This is an exciting time for patients and their eye care providers to have a new option to address the signs and symptoms of dry eye disease. TearBio's nasal spray differentiated mechanism of action is believed to activate the trigeminal parasympathetic pathway, resulting in increased production of basal tear film as a treatment for dry eye disease. Basal tear film is responsible for lubricating, nourishing, and protecting the cornea. Oyster Point sales teams are launching tear via nasal spray during a season when the signs and symptoms of dry eye disease can be further exacerbated by cold weather or living and working in dry environments. We look forward to supporting patients and allowing them to experience Tiravaya nasal spray when they may need it the most. As we have previously highlighted, our commercial strategy includes promoting accelerated payer adoption through early introduction of OysterPoint and Tiravaya to the top payer organizations. John will share more details around our progress with payers later in the call. As we launched here, there are a number of major ophthalmology meetings that are important for Oyster Point to attend for the remainder of 2021. This week, we are attending the 2021 American Academy of Ophthalmology meeting in Boston that started on November 3rd and will go until November 6th. Oyster Point Pharma will have three accepted abstracts presented at this meeting. Later this month is the 2021 American Academy of Ophthalmology meeting that will be held in New Orleans November 12th through the 15th. OysterPoint has an additional three accepted abstracts that will be presented at this meeting as well. Our vision and focus on bringing innovative and transformative ophthalmic disease treatment to patients and building OysterPoint Pharma into a best-in-class ophthalmology company remains our primary goal as a company. I would like to turn the call over to John Cizarenko, OysterPoint's Chief Commercial Officer, to discuss our ongoing efforts for the commercial launch of PureBio nasal spray for the treatment of signs and symptoms of dry eye disease in Q4 of 2021.